Report

Color-coded imaging of splenocyte-pancreatic cancer cell interactions in the tumor microenvironment

Michele McElroy,1 Sharmeela Kaushal,1 Michael Bouvet1 and Robert M. Hoffman1,2,*

1Department of Surgery; University of California; San Diego, California USA; 2AntiCancer, Inc.; San Diego, California USA

Abbreviations: TME, tumor microenvironment; IV, intravenous; IP, intraperitoneal; PET, positron emission tomography; SPET, single photon emission tomography; MRI, magnetic resonance imaging

Key words: pancreatic cancer, tumor microenvironment, cancer immunity, GFP, RFP, tumor imaging

In spite of advances in surgical and medical care, pancreatic cancer remains a leading cause of cancer-related death in the United States. An understanding of cancer-cell interactions with host cells is critical to our ability to develop effective antitumor therapeutics for pancreatic cancer. We report here a color-coded model system for imaging cancer cell interactions with host immune cells within the native pancreas. A human pancreatic cancer cell line engineered to express green fluorescent protein (GFP) in the nucleus and red fluorescent protein (RFP) (DsRed2) in the cytoplasm was orthotopically implanted into the pancreas of a nude mouse. After 10–14 days, red or green fluorescent splenocytes from immune-competent transgenic-mouse donors expressing RFP and GFP, respectively, were delivered systemically to the pancreatic cancer-bearing nude mice. Animals were imaged after splenocyte delivery using high-resolution intravital imaging systems. At 1 day after iv injection red- or green-fluorescent spleen cells were found distributed in lung, liver, spleen and pancreas. By 4 days after cell delivery, however, the immune cells could be clearly imaged surrounding the tumor cells within the pancreas as well as collecting within lymphatic tissues such as lymph nodes and spleen. With the high-resolution intravital imaging afforded by the Olympus IV100 and OV100 systems, the interactions of the dual-colored cancer cells and the red- or green-fluorescent spleen cells could be clearly imaged in this orthotopic pancreatic cancer model. This color-coded in vivo imaging technology offers a novel approach to imaging the interactions of cancer and immune cells in the tumor microenvironment (TME).

Introduction

Although its annual incidence is rare, pancreatic cancer nevertheless represents the 4th leading cause of cancer-related deaths in the United States with the number of cases diagnosed annually roughly equal to its annual mortality rate.1 Despite recent advances in surgical and medical care, little progress has been made in our treatment for this disease, and those diagnosed with this cancer have a 5-year survival rate of less than 5%.2 The highly lethal nature of this disease is partly explained by its often late stage of presentation but is also due to the aggressive nature of these tumors, which rapidly invade local structures and metastasize by both the hematogenous and lymphatic routes.3,4

One of the hallmark features of this cancer is its prominent desmoplastic reaction around the tumor cells.5,6 In addition to extracellular matrix (ECM) proteins and blood vessels, this fibrous tissue contains abundant stromal cells.5,7 These stromal cells are believed to play a role not only in the generation of the abundant desmoplastic reaction but may also influence the progression of the disease.7,8

These recent findings highlight the importance of understanding the impact of the tumor microenvironment on cancer progression.

Both local and distant immune cell interactions with tumor cells may also influence the progression of disease.9-11 The relationship between host inflammation and cancer development and propagation has been the subject of study since Virchow12 and remain a poorly understood component of cancer biology. Immune cells have been shown to participate in regulation of angiogenesis,13,14 tissue remodeling and tumor invasion,15,16 and may even prepare pre-metastatic sites for eventual tumor cell deposition.17-19 These findings highlight the importance of elucidating the nuances of the tumor-host interactions which occur within the TME and beyond in order to better understand the mechanisms of tumor growth and metastasis.

Current methods to image tumor and host interactions have utilized a number of different approaches, each with their own sets of advantages and disadvantages. Noninvasive imaging using magnetic resonance imaging (MRI), positron emission tomography (PET) and single photon emission tomography (SPET) allow whole-body imaging but lack the single-cell and subcellular resolution that can be achieved using intravital microscopy.20 Likewise, luciferase reporter gene expression can facilitate whole-body imaging of cell population distribution but does not allow imaging of individual cell interactions.21 Fluorescence imaging technology offers the capacity for multicolor, high-resolution intravital imaging which can be achieved in a living model system.22,23 We report here a novel in vivo intravital multicolor model system which facilitates the real-time high-resolution imaging of cancer and immune-cell interactions within the microenvironment of the murine pancreas.
Results

In vivo intravital imaging of in situ pancreatic tumors allows for multicolor single-cell resolution imaging of cancer cell interactions with surrounding splenocyte cells. By opening a small abdominal window and exposing the tail of the mouse pancreas with the in situ tumor, we have been able to achieve high-resolution multicolor fluorescence imaging of tumor-immune cell interactions within the living mouse. Rapid image acquisition times allow for multi-filter acquisition of single images as well as in multicolor video acquisition in real time. GFP- or RFP-expressing splenocytes were delivered by intravenous injection to pancreatic tumor-bearing mice, and the interaction of these green fluorescent spleen cells with GFP-RFP pancreatic cancer micrometastases was imaged in vivo using the Olympus OV100 Small Animal Imaging System (Fig. 1).

By varying the filter sets with which the color image is acquired, this imaging technique allows for discrimination between the green (GFP) and red (DsRed2) signals. The GFP long-pass filter set allows the acquisition of both GFP (emission peak 510 nm) and DsRed (emission peak 580 nm) signals simultaneously, facilitating real-time observation of multicolor fluorochrome interactions between immune cells and tumor micrometastases. Figures 1A and B; and 2A show several images of GFP-expressing splenocytes interacting in vivo with GFP-RFP pancreatic cancer micrometastases, while Figure 3A shows the interaction of DsRed-expressing spleen cells with micrometastatic GFP-RFP pancreatic tumors. Segregation of the two distinct fluorophore signals by the use of GFP- and RFP-bandpass filter systems allows for discrimination between the two signals and validation of the multicolor imaging (Figs. 2B and C; 3B and C).

In addition, the use of GFP-RFP cancer cells in this model system yields information about cancer cell integrity within the context of these in vivo interactions with immune cells. Cancer cells with intact nucleus and cytoplasm appear to have a red fluorescent cell body with a yellow nucleus due to the overlap of the GFP (green) and DsRed2 (red) signals. Larger groups of cells under low magnification appear yellow to orange under the GFP long-pass filter (Figs. 1A and B; and 2A), whereas individual cells under high magnification appear red and yellow (Fig. 3A). Nonviable cancer cell fragments consisting of either cytoplasm or nuclei can be discriminated under high magnification as the nuclei alone are brightly green under either GFP long-pass or GFP bandpass filter acquisition (Fig. 3A and B) and the cytoplasm alone appears to be a dim orange under GFP long-pass and a dim red under RFP bandpass filter acquisition (Fig. 3A and C).

Using this imaging strategy, intravital imaging of tumor and immune cell interactions can be achieved in real time within the pancreas. Splenocytes from mice engineered to express either DsRed or GFP were delivered to GFP-RFP pancreatic tumor-bearing or naive mice. The distribution of splenocytes in the recipient animals could be imaged in vivo using the Olympus OV100. In the tumor-bearing animals, the fluorescent spleen cells were initially broadly distributed within the animal and especially prevalent in the lungs, liver and spleen. A few fluorescent splenocyte cells could be found within the pancreas at one day post-injection, but the numbers were very low. After four days, however, in vivo imaging of the recipient tumor-bearing pancreas revealed large aggregates of fluorescent immune cells within the pancreatic tissue especially around peritumoral blood vessels. At nine days after systemic delivery of fluorescent splenocytes to tumor-bearing animals, the immune cell aggregates were even more prominent, again predominantly localizing to blood vessels at the periphery of the tumor. After fifteen days, however, the number of fluorescent immune cells within the peritumoral pancreatic tissue had greatly decreased. Animals without pancreatic tumors were likewise given intravenous injections of either GFP- or DsRed-expressing splenocytes. In these control animals, there was minimal aggregation of immune cells within the pancreatic parenchyma at either one, four or fifteen days after splenocyte delivery (data not shown).

Single-cell resolution imaging can be improved down to the subcellular level by using the Olympus IV100 Intravital Scanning Laser Microscope. For complete stabilization of the tissues the animals are sacrificed immediately prior to imaging. Focusing on the interface of small pancreatic tumors with surrounding GFP-expressing immune cells yields high-resolution subcellular multicolor images of splenocyte homing to the tumor margin within the intact pancreas (Fig. 4). These ultra-high-resolution in situ images show a high density of GFP-expressing splenocytes in the periphery of the GFP-RFP tumors.

Intraperitoneal injection of GFP-expressing splenocytes to GFP-RFP pancreatic tumor-bearing mice likewise yielded immune-cell homing to peritumoral pancreatic tissues within four days of splenocyte injection (Fig. 5). In vivo intravital imaging using the Olympus OV100 at day one after injection demonstrated very few fluorescent immune cells within the pancreas. However, by day four there were numerous collections of green-fluorescent splenocytes within pancreatic tissue adjacent to the tumor. The number of peritumoral fluorescent splenocytes increased up until day nine and again was diminished by day fifteen. The immune cells in these animals were sometimes found immediately adjacent to blood vessels (Fig. 5A). Again, in non-tumor-bearing animals, there were very
Color-coded imaging of the tumor microenvironment

Discussion

The tumor microenvironment is a fundamental part of cancer growth and progression. We describe here a model system which allows multicolor, intravital in vivo evaluation of pancreatic cancer cells and immune cells within the native environment of the pancreas. Splenocytes from immune-competent mice expressing with GFP or DsRed homed to the orthotopic pancreatic tumors within 4 days of systemic administration. In non-tumor bearing animals, there were very few splenocytes present within the pancreas at any time point. Fluorescent splenocytes could also be imaged interacting with peritumoral micrometastases within the pancreas in living mice. The use of GFP-RFP cancer cells expressing GFP in the nucleus and DsRed2 in the cytoplasm allowed the cancer cells to be distinguished from the fluorescent immune cells as well as from cancer cell fragments.

Previous imaging techniques which have imaged tumor-host interactions within orthotopic model systems have largely relied on low-resolution noninvasive imaging with or without additional contrast agents to enhance imaging sensitivity. A few more recent model systems have been developed which utilize fluorescence intravital imaging technology to evaluate tumor-host interactions. Lewis et al., report the use of fluorescent-labeled cowpea mosaic virus for in vivo vascular imaging in both mouse and chick embryo models with a signal duration of approximately 72 hours. Swirski et al., utilized mammalian leukocytes transiently labeled with a near-infrared probe to track immune responses using both whole-body and intravital imaging. In this model, the ex-vivo labeled immune cells maintain their fluorescence signal for 3 days in vivo. Our group has recently utilized stably transduced tumor cell lines which express GFP in the nucleus and DsRed2 in the cytoplasm to image tumor-host interactions in vivo. Fluorescent-protein-based imaging has the advantage of allowing multicolor in vivo imaging in the context of cells which stably express fluorophore, facilitating repeated imaging over time in the same animal. None of these previously published models, however, have evaluated tumor-host interactions within the pancreatic cancer microenvironment using in vivo multicolor intravital imaging.
We present here high-resolution imaging of tumor-immune cell interactions within the native microenvironment of pancreatic cancer. This novel imaging model system facilitates the observation of immune cell interactions with pancreatic cancer cells within the orthotopic tumor microenvironment over time. In this orthotopic model of pancreatic cancer, we are able to visualize the homing of fluorescent spleen cells to the tumor-bearing pancreas and to micrometastatic lesions within the pancreatic parenchyma. This technique achieves high-resolution imaging of cancer cell and immune cell interactions within the pancreatic cancer microenvironment in the living animal, improving our ability to study tumor-host interactions in vivo.

**Materials and Methods**

**Cell culture.** The human pancreatic cancer cell line XPA1 was a gift from Dr. Anirban Maitra at Johns Hopkins University. Cells were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine from Gibco-BRL, Life Technologies, Inc., (Grand Island, NY). All media were supplemented with penicillin/streptomycin (Gibco-BRL), L-glutamine (Gibco-BRL), MEM nonessential amino acids (Gibco-BRL), sodium bicarbonate (Cellgro, Herndon VA), and sodium pyruvate (Gibco-BRL). All cell lines were cultured at 37°C with 5% CO₂.

**Production of the histone H2B-GFP vector.** The histone H2B-GFP fusion gene was inserted at the HindIII (Caal) site of the pLHCX plasmid (Clontech Laboratories, Inc., Mountain View CA) containing the hygromycin resistance gene. Plasmids were transfected into PT67 packaging cells cultured in DMEM (Gibco-BRL) with 10% FBS using the LipofectAMINE system (Gibco-BRL). PT67 cells at 70% confluence were incubated with the LipofectAMINE reagent and the pLHCX-H2B-GFP plasmid for 18 hours, at which point the medium was replenished. Forty-eight hours later the cells were examined by fluorescence microscopy and vector production was accomplished via growth in PT67 packaging cells cultured in the presence of 200–400 μg/mL hygromycin for 7 days.

**Production of the DsRed2 retroviral vector.** The HindIII/NotI fragment of pDsRed2 (Clontech Laboratories, Inc.) was inserted into the HindIII/NotI site of the pLNCX2 plasmid (Clontech Laboratories, Inc.) containing the neomycin resistance gene to produce the pLNCX2-DsRed2 plasmid. Plasmids were transfected into PT67 packaging cells as described above using the LipofectAMINE system (Gibco-BRL). Vector production was accomplished via growth in PT67 packaging cells cultured in the presence of 200–1000 μg/mL G418 for 7 days.

**Production of a GFP-RFP pancreatic cancer cell line.** XPA1 cells were first stably transduced to express DsRed2 in the cytoplasm by incubation with supernatant from PT67 cells transfected with the pLNCX2 plasmid containing the pDsRed2 gene for 72 hours. After transduction, the cells were harvested and subcultured in selective media containing G418 increased in stepwise fashion from 200 to 800 mg/mL. The cells were then incubated for 72 hours in supernatant from PT67 cells transfected with the pLHCX plasmid containing the H2B-GFP fusion gene. After 72 hours the cells were grown in selective medium containing hygromycin. The level of hygromycin was increased in a stepwise fashion up to 400 mg/mL.

The resultant XPA1-GFP-RFP cells expressed DsRed2 in the cytoplasm and GFP in the nucleus.

**Animal care.** Athymic nude mice and C57/B6 mice engineered to express either dsRed or GFP fluorescent proteins were maintained in a barrier facility on high efficiency particulate air (HEPA)-filtered racks. The animals were fed with autoclaved laboratory rodent diet (Tekland LM-485; Western Research Products, Orange, CA). All surgical procedures and imaging were performed with the animals anesthetized by intramuscular injection of 0.02 mL of a solution of 50% ketamine, 38% xylazine and 12% acepromazine maleate. All animal studies were conducted in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Animals.
Establishing dual-colored orthotopic pancreatic tumors. Orthotopic human pancreatic cancer xenografts from the pancreatic cancer cell line XPA1-GFP-RFP were established in nude mice by orthotopic implantation. Four-to-six week old female nude mice were anesthetized as described, and a small transverse incision was then made in the left lateral flank through the skin and peritoneum. The tail of the pancreas was exposed and 1 x 10⁶ XPA1-GFP-RFP cells in 30 μL final volume were injected into the pancreatic tail. The pancreas was then returned to the abdomen, and the peritoneum and skin were closed using 6-0 polyorb surgical suture (US Surgical). Tumors were allowed to grow for 10–14 days prior to the injection of fluorescent splenocytes.

Transgenic GFP and DsRed mice. Transgenic C57/B6-GFP mice were obtained from Prof. Masaru Okabe from the Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.53 These mice express GFP under the control of the chicken β-actin promoter and cytomegalovirus enhancer. All tissues in this animal with the exception of erythrocytes and hair express GFP. Transgenic DsRed mice were purchased from Jackson Laboratories. These mice express DsRed under the control of the chicken β-actin promoter and cytomegalovirus enhancer.34 All tissues with the exception of hair and erythrocytes express DsRed in these animals. Transgenic DsRed mice were crossed with C57/B6 mice to generate transgenic C57/B6-DsRed mice.

Splenocyte harvest. C57/B6 mice engineered to express either DsRed or GFP in all tissues were used for splenocyte acquisition. Animals were euthanized, and their spleens were harvested under sterile conditions. The splenic tissue was first sectioned into pieces with the exception of erythrocytes and hair express DsRed under the control of the chicken β-actin promoter and cytomegalovirus enhancer. All tissues with the exception of hair and erythrocytes express DsRed in these animals. Transgenic DsRed mice were crossed with C57/B6 mice to generate transgenic C57/B6-DsRed mice.

Splenocyte injection. Both tumor-bearing and non-tumor-bearing (control) mice were given a single injection of DsRed or GFP-expressing splenocytes in 100 μL volume at a final cell concentration of 5 x 10⁸ cells/mL. Injections were given either intravenously (via tail vein injection) or intraperitoneally.

Animal imaging. Mice were injected using either the Olympus OV100 Small Animal Imaging System (Olympus Corp., Tokyo, Japan), containing an MT-20 light source (Olympus Biosystems Planegg, Germany) and DP70 CCD camera (Olympus Corp., Tokyo, Japan), or the Olympus IV100 Intravital Scanning Laser Microscope (Olympus Corp., Tokyo, Japan). For imaging on the OV100, animals were deeply anesthetized as described. For imaging on the IV100, animals were sacrificed immediately prior to image acquisition. In each case, the pancreas was exposed via a midline abdominal incision at the time of imaging. All images were analyzed using Image-J (National Institute of Health Bethesda, MD) and were processed for contrast and brightness with the use of Photoshop Elements-4 (Adobe Systems Inc., San Jose, CA).

Acknowledgements
This work was supported in part by grants Cancer Therapeutics Training Program (TE CA 121938), National Institute of Health (CA 109949-03), American Cancer Society (RSG-05-037-01-CCE) (M.B.) and National Cancer Institute (CA 099258 and CA 103563) (AntiCancer Inc.).

References


